Antilymphocyte immunoglobulin (horse) is a primarily IgG immune globulin used to manage allograft rejection in renal transplant patients. Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes.
- Primary indication
- For prevention of renal transplant rejection and for the treatment of aplastic anemia.Curator reviewed · 9 structured indications
- First approval
- Canada, 2003 · United States, 1981
- Also known as
- Anti-thymocyte Globulin (Equine) · Anti-thymocyte globulin equine · e-ATG · eATG · Equine Anti-Thymocyte Globulin
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of December 21, 2025
Which other approved drugs treat the same conditions as Antilymphocyte immunoglobulin (horse), and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account